A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

• Status: Recruiting
• Trial end date: 2025-12-01

Summary

This study aims to provide a basis for further clinical development of CN201.

• Phase: Phase 1

Details

• Lead Sponsor: Curon Biopharmaceutical (Shanghai) Co.,Ltd